Qurient

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

Notice

2023-04-28	큐리언트 "Q702, 국제학회서 희귀혈액암 치료 대안으로 소개"
2023-04-20	큐리언트 "Q901, '합성된 합성치사' 항암 기전 추가 확인"
2023-04-18	큐리언트 "면역항암제 'Q702', 1상서 항암면역 활성화 입증"
2023-04-03	큐리언트, 항암치료제 Q901 국내 임상 1/2상 임상시험계획 승인 신청
2023-03-16	큐리언트, CDK7 표적 항암제 적응증 확장 연구 결과 발표

Company

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More
Business philosophy

Innovation for unmet medical needs

Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More
Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More
IR/PR

Dear Qurient shareholders

Qurient would like to share brief updates on current progress made on its portfolio programs. See More